Close Menu

NEW YORK (GenomeWeb) – Dako, an Agilent subsidiary, has declared CE Mark self-certification for its PD-L1 IHC 22C3 pharmDx, a companion diagnostic to identify best responders to Merck's anti-PD-1 immunotherapy Keytruda (pembrolizumab).

Dako developed the PD-L1 IHC 22C3 pharmDx test in partnership with Merck. By affixing a CE Marking on a product, the manufacturer is declaring that it is in conformity with EU legislation and requirements and can now be sold throughout the European Economic Area.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
03

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
10

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.